ReviewOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2016
Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review.
Review in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- The Genetics of Atypical Femur Fractures-a Systematic Review.Current osteoporosis reports · 2021Pooled it
- Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society.The Journal of clinical endocrinology and metabolism · 2020Guideline
- ["Paradoxical fractures": pathological fractures under anti-osteoporotic and antirheumatic treatment].Zeitschrift fur Rheumatologie · 2025Review
- Bilateral Atypical Femoral Fracture in a Bisphosphonate-Naïve Patient with Prior Long-Term Denosumab Therapy: A Case Report of the Management Strategy and a Literature Review.Journal of clinical medicine · 2024Article
- Position Statement: Atypical Femoral Fracture from the Korean Society for Bone and Mineral Research in 2023.Journal of bone metabolism · 2023Article
- Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system.Scientific reports · 2023Article
- Bilateral Atypical Femoral Fractures after Bisphosphonate Treatment for Osteoporosis: A Literature Review.Journal of clinical medicine · 2023Review
- Incidence of Atypical Femoral Fractures in Patients on Osteoporosis Therapy-A Registry-Based Cohort Study.JBMR plus · 2022Article
- Bilateral Subtrochanteric Complete Atypical Femoral Fracture in a Patient With Rheumatoid Arthritis: A Case Report.Cureus · 2022Article
- Evaluation and management of atypical femoral fractures: an update of current knowledge.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2021Review
- Should denosumab treatment for osteoporosis be continued indefinitely?Therapeutic advances in endocrinology and metabolism · 2021Review
- Clinical Features and Outcomes of Bilateral Atypical Femoral Fractures.Case reports in orthopedics · 2020Article
- Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review.International journal of molecular sciences · 2019Review
- New and emerging concepts in the use of denosumab for the treatment of osteoporosis.Therapeutic advances in musculoskeletal disease · 2018Review
- Atypical femur fracture in a woman with osteogenesis imperfecta and multiple myeloma.Journal of musculoskeletal & neuronal interactions · 2018Article
- Current Understanding of Epidemiology, Pathophysiology, and Management of Atypical Femur Fractures.Current osteoporosis reports · 2018Review
- Denosumab: an Emerging Therapy in Pediatric Bone Disorders.Current osteoporosis reports · 2017Review
- Atypical femoral fractures mimicking metastatic lesions in 2 patients taking denosumab.Acta orthopaedica · 2017Article
- Denosumab for the treatment of osteoporosis.Osteoporosis and sarcopenia · 2017Review
- Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.Expert opinion on biological therapy · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis remains a chronic and common disease associated with high medical costs. Pharmacological therapy has shown to be a good strategy to significantly reduce fracture risk. While literary evidence for bone protection in the short and medium term is strongly in it's favor, there are concerns about long-term treatment with antiresorptive drugs. Increased risk of atypical femoral fractures (AFFs) have been demonstrated in several studies following the long-term use of bisphosphonate. Denosumab offers an alternative approach to the treatment of osteoporosis, however, it is also an antiresorptive drug. We present a case of simultaneous bilateral atypical femoral fractures in a patient with denosumab treatment. These findings highlight the need to reevaluate the optimal antiresorptive therapy duration, as well as the safety of transition from bisphosphonates to denosumab and the need for continued monitoring in the prevention of AFFs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.